Abstract
A 69-year-old Japanese woman who had never smoked had lung adenocarcinoma harboring epidermal growth factor receptor mutation. After 8 months of gefitinib treatment, salvage pneumonectomy was performed. Microscopic examination showed that non-responsive adenocarcinoma remained although necrosis was prominent. Postoperatively, the patient developed empyema that was successfully managed. The postoperative empyema after treatment with gefitinib should be noted, as well as the finding that residual viable tumor cells remained even after the dramatic radiographic response.
Keywords:
Antineoplastic agents; epidermal growth factor receptor; gefitinib; non-small-cell carcinoma; salvage therapy.
MeSH terms
-
Adenocarcinoma / enzymology
-
Adenocarcinoma / genetics
-
Adenocarcinoma / pathology
-
Adenocarcinoma / therapy*
-
Adenocarcinoma of Lung
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Biopsy
-
Chemotherapy, Adjuvant
-
Empyema, Pleural / etiology
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / genetics
-
ErbB Receptors / metabolism
-
Female
-
Gefitinib
-
Humans
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Lymph Node Excision
-
Mutation
-
Neoadjuvant Therapy*
-
Neoplasm, Residual
-
Pneumonectomy* / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / therapeutic use*
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
Tumor Burden
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
EGFR protein, human
-
ErbB Receptors
-
Gefitinib